Liraglutide as Add-On Therapy to Insulin in Type 2 Diabetes Mellitus: A Retrospective, Observational Study From a Daily Clinical Practice Setting in Switzerland

Diabetes Therapy - United States
doi 10.1007/s13300-014-0093-8
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Is a Switch From Insulin Therapy to Liraglutide Possible in Japanese Type 2 Diabetes Mellitus Patients?

Journal of Clinical Medicine Research
2014English

Retrospective Analysis of an Insulin-To-Liraglutide Switch in Patients With Type 2 Diabetes Mellitus

Diabetes Therapy
Internal MedicineEndocrinologyMetabolismDiabetes
2018English

Type 2 Diabetes Mellitus Management: A Retrospective Study in Rural General Practice

Advances in Diabetes and Metabolism
2019English

Adherence to Liraglutide Once Daily or Exenatide Once Weekly Over a 12-Month Period Among Commercially Insured Patients With Type 2 Diabetes Mellitus: A Retrospective Observational Study

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2015English

Superior Efficacy of Insulin Degludec/Liraglutide Versus Insulin Glargine U100 as Add-On to Sodium-Glucose Co-Transporter-2 Inhibitor Therapy: A Randomized Clinical Trial in Patients With Uncontrolled Type 2 Diabetes

Diabetes, Obesity and Metabolism
Internal MedicineEndocrinologyMetabolismDiabetes
2019English

Observational Study of the Use of Insulin Glargine as Basal Therapy in Patients With Type 2 Diabetes Mellitus in Morocco

Journal of Endocrinology and Metabolism
EndocrinologyMetabolismDiabetes
2015English

Metformin as a Safe Option to Insulin in Gestational Diabetes Mellitus: A Retrospective Study

SN Comprehensive Clinical Medicine
2020English

Cost-Utility Analysis of Liraglutide Compared With Sulphonylurea or Sitagliptin, All as Add-On to Metformin Monotherapy in Type 2 Diabetes Mellitus

Diabetic Medicine
Internal MedicineEndocrinologyMetabolismDiabetes
2012English

Comparative Outcomes of Basal Insulin and Oral Anti-Diabetic Agent as an Add-On to Dual Therapy in Patients With Type 2 Diabetes Mellitus

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy